Stockscreener 앱 받기
4.95
0.00%
0.00
Exicure Inc 주식(XCUR)의 최신 뉴스
Volume spikes in Exicure Inc. stock – what they mean2025 EndofYear Setup & Fast Entry High Yield Tips - newser.com
Building trade automation scripts for Exicure Inc.July 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
Will Exicure Inc. bounce back from current supportWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - newser.com
Exicure’s (XCUR) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World
Can Exicure Inc. (2H0) stock attract analyst upgradesSwing Trade & Expert Verified Stock Movement Alerts - newser.com
Should you hold or exit Exicure Inc. now2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Is Exicure Inc. (2H0) stock a safe buy pre earningsJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com
How analysts revise price targets for Exicure Inc. (2H0) stockJuly 2025 Final Week & Risk Managed Investment Signals - newser.com
Will Exicure Inc. stock reach Wall Street targets2025 Dividend Review & Verified Entry Point Detection - newser.com
Chart overlay techniques for tracking Exicure Inc.2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com
Exicure’s burixafor nears phase 2 data readout in multiple myeloma By Investing.com - Investing.com Nigeria
Exicure Highlights Recent Achievements and Near-Term Strategic Priorities - MarketScreener
Will breakout in Exicure Inc. lead to full recoveryPortfolio Update Summary & AI Based Buy and Sell Signals - newser.com
Exicure (XCUR) Progresses with Promising Results in Phase 2 Buri - GuruFocus
Exicure’s burixafor nears phase 2 data readout in multiple myeloma - Investing.com
Exicure Inc 2H0 Stock Analysis and ForecastTake Profit Strategies & Free Tremendous Portfolio Expansion - earlytimes.in
Exicure Reports Progress in Burixafor (GPC-100) Phase 2 Trial for Multiple Myeloma and Plans Expansion into Sickle Cell Disease and AML with New Leadership Appointments - Quiver Quantitative
Burixafor Phase 2 shows promising interim mobilization results; topline readout due in - Stock Titan
Is Exicure Inc. (2H0) stock a defensive play amid uncertaintyMarket Risk Summary & Verified Swing Trading Watchlist - newser.com
Can technical indicators confirm Exicure Inc.’s reversalWeekly Investment Recap & Fast Exit and Entry Strategy Plans - newser.com
Using flow based indicators on Exicure Inc.July 2025 Opening Moves & Fast Entry and Exit Trade Plans - newser.com
Will Exicure Inc. (2H0) stock benefit from sector leadershipEntry Point & Stock Market Timing Techniques - newser.com
Why Exicure Inc. (2H0) stock appeals to dividend investorsWeekly Investment Summary & Daily Volume Surge Trade Alerts - newser.com
Is Exicure Inc. (2H0) stock a buy before earnings resultsWeekly Trade Summary & Real-Time Buy Signal Notifications - newser.com
Risk vs reward if holding onto Exicure Inc.Weekly Market Summary & Reliable Intraday Trade Alerts - newser.com
Is Exicure Inc. (2H0) stock a fit for income portfoliosMarket Activity Recap & Community Verified Watchlist Alerts - newser.com
Developing predictive dashboards with Exicure Inc. dataEarnings Beat & Technical Entry and Exit Alerts - newser.com
Is Exicure Inc a good long term investmentBullish Engulfing Patterns & See Risk Factors Before Making Any Move - earlytimes.in
What analysts say about Exicure Inc 2H0 stockMarket Liquidity Analysis & Explosive Growth Trading - earlytimes.in
0.86%
자본화:
|
볼륨(24시간):